Canntab Therapeutics Ltd. said Sheldon Inwentash resigned from its board to pursue other opportunities.
The Canada-based company develops advanced pharmaceutical-grade formulations of cannabinoids.
Canntab Therapeutics director resigns
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Canntab Therapeutics Ltd. said Sheldon Inwentash resigned from its board to pursue other opportunities.
The Canada-based company develops advanced pharmaceutical-grade formulations of cannabinoids.